Abstract 6655: Tumor microenvironment evaluation and tumor intrinsic genomic features predict anti-PD-1 response of metastatic gastric cancer: Results from phase II clinical trial and multi-omics data

2020 ◽  
Author(s):  
Dongqiang Zeng ◽  
Wangjun Liao ◽  
Kyoung Mee Kim ◽  
Min Shi ◽  
Rui Zhou ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Tumor Microenvironment ◽  
Phase Ii ◽  
Metastatic Gastric Cancer ◽  
Phase Ii Clinical Trial ◽  
Omics Data ◽  
Genomic Features

scholarly journals Phase II clinical trial of S‐1 plus nanoparticle albumin‐bound paclitaxel in untreated patients with metastatic gastric cancer

2018 ◽  
Vol 109 (11) ◽  
pp. 3575-3582 ◽  
Author(s):  
Ming‐ming He ◽  
Feng Wang ◽  
Ying Jin ◽  
Shu‐qiang Yuan ◽  
Chao Ren ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Phase Ii ◽  
Metastatic Gastric Cancer ◽  
Phase Ii Clinical Trial

Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer

2019 ◽  
Vol 30 (1) ◽  
pp. 98-104 ◽  
Author(s):  
Yosuke Horita ◽  
Michiko Nishino ◽  
Saiho Sugimoto ◽  
Akihiko Kida ◽  
Atsuyoshi Mizukami ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Phase Ii ◽  
Metastatic Gastric Cancer ◽  
Phase Ii Clinical Trial ◽  
Weekly Paclitaxel ◽  
Second Line ◽  
Her2 Positive

Tu1448 Intragastric Injection of Botulinum Toxin a to Treat Gastric Cancer: An Open-Label Phase II Clinical Trial

2016 ◽  
Vol 150 (4) ◽  
pp. S1251-S1252
Author(s):  
Gøran Andersen ◽  
Chun-Mei Zhao ◽  
Xing Cai ◽  
Hanne-Line Rabben ◽  
James G. Fox ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Botulinum Toxin ◽  
Phase Ii ◽  
Botulinum Toxin A ◽  
Phase Ii Clinical Trial ◽  
Open Label ◽  
Toxin A ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document